CG Oncology, Inc. CGON
NASDAQ · United States · Health Technology
$70.89+0.37 (+0.52%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
CGON, YPF, and IE are three of the most popular stocks amongst call traders
CG Oncology stock has delivered very strong 1 year gains, yet the broader valuation checks and current pricing leave investors weighing how much of the story is already reflected in the share price. The stock is up 160.2% over the past year, which means anyone buying today is doing so after a very sharp re rating rather than early in the move. Expectations for CG Oncology to turn its pipeline into durable revenue can support the current valuation, while execution risk around clinical...
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
DALLAS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Cantor Fitzgerald and Morgan Stanley Global Healthcare Conferences in New York City this month. The details of the upcoming events are as follows: Cantor Fitzgerald Global Healthcare ConferencePresentation Time: Wednesday, September 9, 2026 at 8:00am ET Morgan Stanley Global Healthcare C
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.